# University of Cambridge Enterprise

> University of Cambridge Enterprise is a VC fund backing Biotechnology. See 112 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United Kingdom
- Total investments: 112
- Last investment: Dec 2025
- Lead investor: 37%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/cambridge-enterprise
- X (Twitter): http://twitter.com/UCamEnterprise
- Website: http://www.enterprise.cam.ac.uk

University of Cambridge Enterprise is a VC fund in Cambridge focused on Biotechnology and Health Care. University of Cambridge Enterprise, also known as Cambridge Enterprise Seed Funds, consisting of the Challenge Fund and the Venture Fund, is a resource for members of the University of Cambridge and the Babraham Institute. Investments are priced and structured competitively with other sources of early stage seed capital in order to encourageco-investment, follow-on funding and commercialisation of University of Cambridge and Babraham Institute inventions.

## Contacts

5 contacts available for University of Cambridge Enterprise. Shizune tracks 16 team members at University of Cambridge Enterprise. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/university-of-cambridge-enterprise?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 28 | 25% |
| Health Care | 20 | 18% |
| Software | 12 | 11% |
| Medical | 10 | 9% |
| Life Science | 9 | 8% |

77 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 37 | 33% |
| Series A | 30 | 27% |
| Pre-Seed | 12 | 11% |
| Series B | 7 | 6% |
| Funding Round | 6 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 64 | 57% |
| Germany | 1 | 1% |
| Ireland | 1 | 1% |
| United States | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Amanda Wooding | Deputy Head of Life Sciences | 3 | https://shizune.co/investors/profile/amanda-wooding |
| Anne Dobrée | Head of Seed Funds | 1 | https://shizune.co/investors/profile/anne-dobre |
| Christian Pratt | Head of Marketing and Communications | 0 | https://shizune.co/investors/profile/christian-pratt |
| Emma Barker | Senior Commercialisation Associate | 0 | https://shizune.co/investors/profile/emma-barker |
| Georgina Weller | Office Manager | 0 | https://shizune.co/investors/profile/georgina-weller |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nu Quantum | Nu Quantum is a telecommunications company that develops end-to-end quantum cryptography systems.It secures communications within and between cities through urban and satellite free-space optical links. The system helps with the realization of commercial deliverable photonic technologies by combining novel materials and semiconductor technology.This enables clients to secure the exchange of cryptographic keys for the ultra-sensitive detection of light.Yuri Andersson, Mete Atatüre, and Carmen Berraquero founded Nu Quantum in Cambridge, Cambridgeshire in 2018. | $71.1M | Series A | Dec 10, 2025 |  |
| Paragraf | Paragraf is the world’s leading graphene-based electronic device design, development and manufacturing company. Building on our proprietary process to grow graphene directly on standard semiconductor industry substrates, Paragraf has pioneered the delivery of two-dimensional technologies at scale. Paragraf’s high-quality graphene – integratablewith standard semiconductor tool process lines – has unlocked the incorporation of this remarkable material into both existing and new electronic devices and applications. Through our world-first dedicated graphene device foundry, Paragraf delivers high-performance, low-power technologies to multiple markets and offers two-dimensional-material foundry services to customers and partners, providing graphene in chips to their device requirements. | $55M | Series C | Aug 25, 2025 |  |
| xWatts | xwatts is an intelligent energy management system that helps commercial buildings reduce costs and emissions. | $1.8M | Pre-Seed | Jul 18, 2024 |  |
| Wave Photonics | Wave Photonics utilizes computational techniques to accelerate integrated photonics product designs.The company is developing a platform that provides optimized designs and streamlined integration between the supply chain using a software tool for predicting the performance and variation of a component for a given fabrication process and anoptimizer to generate a foundry-specific component library.Wave Photonics is headquartered in Cambridge, UK | $5.7M | Seed | Jun 20, 2024 |  |
| Echion Technologies | Echion Technologies specializes in developing advanced anode materials for Li-ion batteries. Their XNO® material boasts faster charging times, longer lifespans, and improved safety compared to traditional options. Echion targets the heavy-duty electric vehicle market, aiming to improve efficiency and sustainability within the transportation sector. | $37M | Series B | Jun 13, 2024 |  |
| Zetta Genomics | Zetta Genomics manages large-scale genomic data for precision medicine. The company employs distributed database technology and best practice security techniques to leverage genomic data benefits while preserving data privacy. Zetta Genomics was founded in 2018 and is based in Cambridge, England. | $2.3M | Seed | Feb 08, 2024 |  |
| Xampla | Xampla creates plant protein material for commercial use. Our next generation material performs like synthetic polymers, but decomposes naturally and fully, without harming the environment. | $7M | Venture - Series Unknown | Jan 30, 2024 |  |
| T-Therapeutics | T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. . | $59.6M | Series A | Nov 15, 2023 |  |
| RoboK | VC-backed startup developing software solutions and tools for building and validating AI-based perception. The company's vision is to accelerate the deployment of affordable autonomy solutions for automotive and industrial applications. | $2M | Seed | Jun 29, 2023 |  |
| Planetary Processing | Planetary Processing provides an SDK for the creation and operation of massively-multiplayer online games. Simplifying the creation and maintenance of large online games allows game studios to focus on game development instead of infrastructure. | $1.3M | Pre-Seed | Jun 07, 2023 |  |

10 of 112 investments shown.

## Co-investors
- [Parkwalk Advisors](https://shizune.co/investors/profile/parkwalk-advisors) — VC Fund, 42 deals together
- [Cambridge Angels group](https://shizune.co/investors/profile/cambridge-angels-group) — VC Fund, 19 deals together
- [Martlet Capital](https://shizune.co/investors/profile/martlet) — VC Fund, 19 deals together
- [Amadeus Capital Partners](https://shizune.co/investors/profile/amadeus-capital-partners) — VC Fund, 16 deals together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 15 deals together
- [IQ Capital](https://shizune.co/investors/profile/iq-capital-partners) — VC Fund, 14 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does University of Cambridge Enterprise invest in?

University of Cambridge Enterprise invests primarily in Biotechnology, Health Care and Software startups, most often at Seed and Series A stage. Most of the 112 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact University of Cambridge Enterprise?

Public channels for University of Cambridge Enterprise include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at University of Cambridge Enterprise?

The team at University of Cambridge Enterprise includes Amanda Wooding (Deputy Head of Life Sciences), Anne Dobrée (Head of Seed Funds) and Christian Pratt (Head of Marketing and Communications), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co